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1 Research questions 
The EUnetHTA HTA Core Model® for Rapid Relative Effectiveness Assess-
ment of Pharmaceuticals was used for structuring this report [1]. The Model 
organises HTA information according to predefined generic research ques-
tions. Based on these generic questions, the following research questions were 
answered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is obinutuzumab? 
A0022 Who manufactures obinutuzumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has obinutuzumab received marketing authorisation? 
Health problem and current use 
A0002 What is FL? 
A0004 What is the natural course of FL? 
A0006 What are the consequences of FL for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of FL? 
A0003 What are the known risk factors for FL? 
A0024 How is FL currently diagnosed according to published guidelines and in practice? 
A0025 How is FL currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of obinutuzumab on mortality? 
D0006 How does obinutuzumab affect progression (or recurrence) of FL? 
D0005 How obinutuzumab affect symptoms and findings (severity, frequency) of FL? 
D0011 What is the effect of obinutuzumab on patients’ body functions? 
D0012 What is the effect of obinutuzumab on generic health-related quality of life? 
D0013 What is the effect of obinutuzumab on disease-specific quality of life? 
Safety 
C0008 How safe is obinutuzumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying obinutuzumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through  
the use of obinutuzumab? 
A0021 What is the reimbursement status of obinutuzumab? 
 
 
 
 
EUnetHTA  
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Obinutuzumab/Gazyvaro®/Gazyva®/L01XC15 
 
B0001: What is obinutuzumab? 
Obinutuzumab is a recombinant monoclonal humanised and glycoengineered 
type II anti-CD20 antibody of the IgG1 subclass. It specifically targets the 
CD20 antigen expressed on the surface of non-malignant and malignant pre-B 
and mature B lymphocytes. Obinutuzumab mediates B-cell lysis through en-
gaging immune effector cells, by activating the intracellular death-signalling 
pathways and by activating the complement cascade. Included in the immune 
effector cell mechanisms are antibody-dependent cellular cytotoxicity (ADCC) 
and antibody-dependent cellular phagocytosis [2, 3].  
Obinutuzumab is available as single-use vials containing 1,000 mg/40 ml (25 
mg/ml). It should be administered as an intravenous infusion but not as an 
intravenous push or bolus. Furthermore, premedication for infusion reactions 
and tumour lysis syndrome is recommended [2, 3].  
The recommended dosage for the treatment of follicular lymphoma (FL) is 
1,000 mg on day 1, followed by 1,000 mg on days 8 and 15 of cycle 1. In cycles 
2–6 1,000 mg are recommended on the respective day 1. Subsequently, 1,000 
mg should be administered every 2 months for 2 years [2].  
 
A0022: Who manufactures obinutuzumab? 
Roche Registration Ltd 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Obinutuzumab in combination with bendamustine, followed by obinutuzu-
mab monotherapy, is indicated for the treatment of FL patients who relapsed 
after or are refractory to a rituximab-containing regimen. 
 
                                                             
1 M = months 
2 Y = years 
anti-CD20 antibody 
cycle 1:  
1,000 mg x day 1, 8, 15 
cycles 2–6: 
1,000 mg day 1 
1,000 mg/2 M1/2 Y2 
obinutuzumab-
bendamustine for 
relapsed/refractory FL 
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4 Current regulatory status 
A0020: For which indications has obinutuzumab received  
marketing authorisation? 
Obinutuzumab was initially approved in July 2014 by the European Medi-
cines Agency (EMA) as combination therapy with chlorambucil for the treat-
ment of patients with untreated chronic lymphocytic leukaemia (CLL), with 
comorbidities making them unsuitable for full-dose fludarabine-based therapy 
[3]. In April 2016, the Committee for Human Medicinal Products (CHMP) 
adopted a positive opinion for the following indication: obinutuzumab as a 
combination therapy with bendamustine followed by obinutuzumab mono-
therapy for the treatment of patients with FL who did not respond or progres-
sed during or up to 6 months after treatment with rituximab or a rituximab-
containing regimen [4]. 
In November 2013, the US Food and Drug Administration (FDA) approved 
obinutuzumab in combination with chlorambucil for the treatment of previ-
ously untreated CLL. In February 2016, obinutuzumab received marketing 
authorisation for combination therapy with bendamustine followed by obinu-
tuzumab monotherapy for the treatment of patients with FL who relapsed 
after or are refractory to a rituximab-containing regimen. This approval was 
based on results of a phase III study, GADOLIN, which is available in abstract 
form only [2, 5]. 
 
 
 
5 Burden of disease 
A0002: What is FL? 
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of diseases that 
arise from distinct lymphocyte types, B or T/NK cells [6, 7]. They can be in-
dolent (slow-growing) or aggressive (fast-growing). The two commonest forms 
of NHL in adults are diffuse large B-cell lymphomas, which are typically ag-
gressive and follicular lymphomas (FL), which are typically indolent [8]. 
 
A0004: What is the natural course of FL? 
FL tumour cells are malignant equivalents of normal germinal centre B cells 
(centrocytes and centroblasts). In combination with a group of cells like mac-
rophages, follicular dendritic cells, fibroblasts, endothelial cells and T lym-
phocytes, they create a disease-specific microenvironment. This enables a bi-
directional feedback mechanism among cancer cells and the network of re-
active cells [9, 10]. Malignant B cells can influence the microenvironment 
through the following mechanisms: skewing the differentiation of immune 
cells, attracting regulatory T cells/suppressive monocytes, and secreting cy-
tokines that promote an immunosuppressive environment [11]. 
 
approved by the EMA 
since 2014 for CLL 
 
positive opinion  
by the CHMP for  
the treatment of FL  
in April 2016 
approved by the FDA 
since 2013 for CLL 
 
approved for the 
treatment of FL  
since 2016 
FL is the most common 
subtype of indolent  
B-cell NHL 
bidirectional feedback 
mechanism between 
cancer cells and  
reactive cells 
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The substantial majority of FL patients are diagnosed at an advanced stage 
[9]. Progression of FL alters from person to person and is contingent on the 
speed of tumour’s growth as well as the involvement of other organs [12]. 
Some people with FL remain asymptomatic for years, although they have 
advanced-stage disease [9, 12]. Over time, some FL patients develop a trans-
formed lymphoma, such as a diffuse large B-cell lymphoma [12, 13].  
 
A0006: What are the consequences of FL for the society? 
A0023: How many people belong to the target population? 
In Austria, 1,265 patients were newly diagnosed with NHL in 2015, equalling 
an incidence rate of 9.0 cases per 100,000 persons. It is estimated that 617 
people are dying due to the disease per year. Age-standardised rates from 2015 
show that incidence (10.7 vs 7.6) and mortality (4.4 vs 2.5) are higher in men 
than in women [14]. NHL is commonly diagnosed in people aged 65–74, which 
results in a median age of 66 years [15]. 
FL is the sixth most common cancer in Europe, accounting for approximately 
3% of all cancers. FL represents about 25% of all NHLs and is the second 
most common subtype of lymphoma in western Europe [16].  
 
A0005: What are the symptoms and the burden of FL? 
The initial symptoms of FL are painless swelling of lymph nodes in the neck, 
arm pits, and/or groin [12, 16]. The compression of vital organs can cause 
symptoms like abdominal/back pain due to affected deep lymph nodes. Oth-
er signs and symptoms of FL may include fatigue, infections, and sometimes 
bleeding. Fever, night sweats as well as unintentional weight loss are known 
as B-symptoms, which are particularly important during the staging process 
[16].  
 
A0003: What are the known risk factors for FL? 
The probability for developing FL is affected by age, gender, and ethnicity. 
FL is less common among Asians and Blacks than among other ethnicities. 
As FL is not an inherited disease, the substantial risk of developing FL is not 
increased in siblings and children of patients [12].  
Other factors that have been associated with the occurrence of FL are life-
style, environmental factors and previous medical conditions; however, their 
influence is not yet clear [16]. 
 
A0024: How is FL currently diagnosed according  
to published guidelines and in practice? 
An excisional tissue biopsy is necessary for the diagnosis of FL, in most in-
stances from a lymph node. To further strengthen a suspected diagnosis, an 
additional histological examination (immunophenotypic and molecular genet-
ic studies) is required. While the majority of patients have systematic follic-
ular lymphoma, three additional clinical variants of FL were classified by the 
WHO in 2008 [10]: 
 paediatric FL 
 intrafollicular neoplasia 
 primary intestinal FL 
often late diagnosis 
1,265 new NHL cases  
in Austria 
sixth most common 
cancer in Europe 
initial symptom: 
painless swelling of 
lymph nodes 
no increased risk in 
relatives of FL patients 
tissue biopsy of the 
lymph nodes for 
diagnosis of FL 
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To determine which stage of disease is present and which parts of the body 
have been affected, different tests are available, e.g. blood tests, bone marrow 
biopsy, computed tomography (CT) scan, positron emission tomography (PET) 
scan. One way to stage FL is dependent on how much of the lymphatic sys-
tem is affected at the time of diagnosis [10]:  
 Stage I – one lymph node region/structure is involved.  
 Stage II – two or more lymph node regions/structures  
on the same side of the diaphragm are involved. 
 Stage III – lymph node regions/structures on both sides  
of the diaphragm are involved. 
 Stage IV – disseminated involvement of several organs or  
tissues other than lymph node regions/structures, like bone marrow. 
Each stage includes an additional letter (A or B) that indicates whether B-
symptoms are present (B) or not (A). Another staging system of the WHO 
(2008) classifies FL into three grades: FL1–2, FL3A and FL3B, based on the 
number of centroblasts [17].  
 
 
 
6 Current treatment 
A0025: How is FL currently managed according  
to published guidelines and in practice? 
To determine a treatment strategy for a patient with FL, the following factors 
have to be taken into account: the extent and size of disease, the establishment 
of the precise histologic subtype, the general health/performance status and 
the patient’s age.  
Since FL is commonly indolent, it can take years for the disease to progress. 
During that time it may not be necessary to apply any therapies, instead, a 
„watch and wait” approach (close observation) can be used [12, 18]. Treatment 
options for patients who suffer from early-stage disease (I and contiguous II) 
are radiation therapy (RT), observation, and chemoimmunotherapy/immuno-
therapy (rituximab) [18, 19]. 
Patients with advanced disease/stage but a low burden may also be observed 
or receive rituximab as a first-line therapy, while the following treatment op-
tions are available for patients who are suffering from a high burden [7, 20]: 
 monotherapy with rituximab/an alkylating agent 
 chemoimmunotherapy (bendamustine plus rituximab, R-CHOP3  
or R-CVP4) 
 maintenance therapy with rituximab or consolidation therapy  
with radio-immunotherapy 
                                                             
3 R-CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone  
plus rituximab 
4 R-CVP = cyclophosphamide, vincristine, and prednisone plus rituximab 
staging according to 
involved lymph nodes or 
the number of 
centroblasts 
for the determination  
of treatment options 
several factors have to 
be taken into account 
treatment options  
for early-stage FL: 
RT, observation, 
chemmoimmunotherapy 
first-line treatment 
options for advanced FL 
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No standard therapies are available for the treatment of relapsed or refracto-
ry FL. However, there are several potential therapies that can be applied, like 
rituximab as monotherapy (poor performance status) or in combination with 
chemotherapy (good performance status). Another option is chemoimmuno-
therapy with R-CVP4, R-CHOP3, rituximab plus bendamustine, or idelalisib 
as monotherapy for rituximab-refractory patients. However, it should be men-
tioned that idelalisib monotherapy is currently monitored due to severe AEs 
[17, 21, 22].  
 
 
 
7 Evidence 
A literature search was conducted on 11 May 2016 in five databases: the Coch-
rane Library, CRD Database, Embase, Ovid Medline and PubMed. Search 
terms were „Obinutuzumab”, „Gazyva”, „ga101”, „r7159”, „ro5072759”, „Lym-
phoma and Non-Hodgkin”. Overall, 275 references were identified through 
systematic literature search. The manufacturer was contacted as well but did 
not respond to our request. Eligible for inclusion were phase III trials (full 
texts, abstracts) and phase II studies published as full text, as well as other 
study designs like results from compassionate-use programmes or meta-anal-
yses. After applying these inclusion criteria, 1 phase III trial available in ab-
stract form and 1 phase I/II trial were included in this report. Additionally, 
FDA approval documents and 24 references identified through manual search 
were included. 
 
 
7.1 Clinical efficacy and safety  
– phase III studies 
GADOLIN [2, 23] was an open-label, multicentre, randomised, phase III 
study comparing obinutuzumab combined with bendamustine to bendamus-
tine monotherapy in patients with rituximab-refractory, indolent NHL. Re-
ported are the efficacy results of the study’s FL population (n = 321) and the 
safety data based on 392 indolent NHL patients, of whom 81% had FL, 12% 
had marginal zone lymphoma, and 7% had small lymphocytic lymphoma. 
The trial was discontinued at the planned interim analysis. 
Rituximab-refractory, CD20-positive patients with indolent NHL were ran-
domised in a 1:1 ratio to receive either obinutuzumab (cycle 1: 1,000 mg on 
days 1, 8 and 15; cycles 2–6: 1,000 mg on day 1 followed by 1,000 mg every 2 
months for up to 2 years) plus bendamustine (cycles 1–6: 90 mg/m2/day on 
days 1 and 2), and after complete response (CR), partial response (PR), or sta-
ble disease (SD), patients received obinutuzumab maintenance therapy (1,000 
mg every two months for two years or until progression); or bendamustine (cy-
cles 1–6: 120 mg/m2/day on days 1 and 2). The stratification of randomisation 
was based on the rituximab-refractory type (refractory to prior rituximab mon-
otherapy vs rituximab in combination with chemotherapy) and the number 
of prior therapies (≤ 2 vs > 2). 
no standard therapies 
for refractory/relapsed 
FL available 
search in 5 databases 
 
273 references in total 
 
 
 
 
 
included: 
1 phase III study 
1 phase I/II study 
GADOLIN: 
randomised phase III 
study 
comparison of 
obinutuzumab-
bendamustine vs 
bendamustine 
monotherapy 
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Enrolled patients were at least 18 years or older with a median age of 63 (rang-
ing from 34 to 87 years). 95% of patients had an ECOG performance status of 
0–1 at baseline. The median number of prior therapies was 2, ranging from 1 
to 10. Detailed patient characteristics including inclusion and exclusion cri-
teria can be found in Table 3. 
The primary outcome of GADOLIN was progression-free survival (PFS) meas-
ured by an independent radiology facility (IRF); secondary outcomes included 
PFS assessed by an investigator, overall survival (OS), best overall response 
(OR), safety outcomes including adverse events (AEs) and health-related qual-
ity of life (HRQoL; assessed by the 42-item Functional Assessment of Cancer 
Treatment-Lymphoma questionnaire). 
 
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of obinutuzumab on mortality? 
The secondary study endpoint, OS, was not yet reached either by the obinu-
tuzumab-bendamustine group or in the bendamustine arm. 
 
D0006: How does obinutuzumab affect progression (or recurrence) of FL? 
The primary endpoint, PFS assessed by an independent radiology facility 
(PFS-IRF), was significantly improved (p < 0.0001) in the obinutuzumab-
bendamustine group compared to the bendamustine arm. Median PSF-IRF 
was 13.8 months in the bendamustine group and was not reached in the ob-
inutuzumab-bendamustine arm. The hazard ratio (HR) for disease progres-
sion for obinutuzumab-bendamustine compared to bendamustine alone was 
0.48 (95% CI 0.34–0.68). 
Median PFS assessed by an investigator (PFS-IA) was 13.7 months in the ben-
damustine group compared to 29.2 months in the obinutuzumab-bendamus-
tine arm. PFS-IA was significantly (p < 0.0001) different between the two ran-
domised groups. The HR for disease progression assessed by an investigator 
for obinutuzumab-bendamustine compared to bendamustine alone was 0.48 
(95% CI 0.35–0.67).  
 
D0005: How does obinutuzumab affect symptoms and findings  
(severity, frequency) of FL? 
The overall response (OR) rates were 78.7% (obinutuzumab-bendamustine) 
and 74.7% (bendamustine); a complete response (CR) was achieved in 15.5% 
of patients in the obinutuzumab-bendamustine group and in 18.7% of pa-
tients in the bendamustine arm. Partial response (PR) rates were 63.2% and 
56.0% in patients receiving obinutuzumab-bendamustine and in patients re-
ceiving bendamustine alone respectively.  
 
D0011: What is the effect of obinutuzumab on patients’ body functions? 
Neutropenia, thrombocytopenia as well as pneumonia can occur in patients 
treated with obinutuzumab. Detailed description of adverse events can be 
found in the section ‘Safety’. 
 
median age 63 years and 
ECOG performance 
status of 0–1 
primary outcome: PFS 
secondary outcomes: 
OS, OR, AEs and HRQoL 
OS was reached by 
neither study group 
primary endpoint: 
PFS-IRF 
 
median PFS-IRF  
was not reached in the 
intervention group 
median PFS-IA:  
O-B arm: 29.2 months 
B arm: 13.7 months 
OR was not  
significantly improved 
O-B: 78.7% 
B: 74.7% 
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D0012: What is the effect of obinutuzumab on generic  
health-related quality of life? 
D0013: What is the effect of obinutuzumab on disease-specific quality of life? 
The obinutuzumab-bendamustine group and the bendamustine arm showed 
similar mean baseline scores in all individual FACT-Lym5 subscales, and 
composite FACT-G6, FACT-TOI7, and FACT total scores. During the treat-
ment period as well as during follow-up, no differences could be noted in the 
average scores between the study arms regarding any of the FACT-Lym5 sub-
scales. The median time to ≥ 6 point worsening from baseline on FACT-TOI7 
was 8.0 months (95% CI, 5.8–15.1) in the obinutuzumab-bendamustine arm 
and 4.6 months (95% CI, 3.8-6.4) in the bendamustine arm (HR = 0.74, 95% 
CI 0.56–0.98) [24].  
Table 1: Efficacy results based on the FL population of the GADOLIN trial  
Descriptive 
statistics and 
estimate 
variability 
Treatment group Obinutuzumab-
bendamustine 
Bendamustine 
Number of subjects 155 166 
Median PFS-IRF8 (95% 
CI), months 
NR 13.8 
Median PFS-IA9 (95% CI), 
months 
29.2 13.7 
OS NR NR 
Best OR10, % 
CR 
PR 
78.7 
15.5 
63.2 
74.7 
18.7 
56.0 
Median duration of DOR, 
months 
NR 11.6 
Effect estimate 
per comparison 
Comparison groups Obinutuzumab-bendamustine 
vs bendamustine 
PFS-IRC8 HR 0.48 
95% CI 0.34–0.68 
Log-rank test p value < 0.0001 
PFS-IA9 HR 0.48 
95% CI 0.35–0.67 
Log-rank test p value < 0.0001 
Abbreviations: CI = confidence interval, CR = complete response, DOR = duration of response, HR = hazard ratio,  
OR = overall response, OS = overall survival, PFS = progression-free survival, PR = partial response 
 
                                                             
  5 FACT-Lym = Functional Assessment of Cancer Therapy – for patients with NHL 
  6 FACT-G = Functional Assessment of Cancer Therapy – general  
  7 FACT-TOI = Functional Assessment of Cancer Therapy – Trial Outcome Index 
  8 PFS-IRF = PFS determined by an independent radiology facility 
  9 PFS-IA = PFS assessed by an investigator 
10 best OR = best response of CR/PR within 12 months of study start 
similar mean baseline 
scores between the two 
study arms 
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7.1.2 Safety 
C0008: How safe is obinutuzumab in relation to the comparator(s)? 
The most common grade 3–4 AEs in both the obinutuzumab-bendamustine 
group and in the bendamustine group were neutropenia (33% vs 26.3%), throm-
bocytopenia (10.8% vs 16.2%), and infusion-related reactions (10.8% vs 5.6%). 
Serious AEs that were most frequently reported in both treatment arms were 
febrile neutropenia (obinutuzumab-bendamustine 4.1%; bendamustine: 3.0%) 
and pneumonia (obinutuzumab-bendamustine: 2.9%; bendamustine: 5.1%).  
During obinutuzumab maintenance treatment, the most common haemato-
logical grade 3–4 laboratory abnormalities were lymphopenia (52%), leuko-
penia (20%) and neutropenia (27%). Chemistry grade 3–4 laboratory abnor-
malities occurred in 8% (hypophosphataemia and hyponatraemia) of patient 
during obinutuzumab monotherapy. Treatment discontinuation due to AEs 
occurred in 11.3% (obinutuzumab-bendamustine) and 15.7% (bendamustine) 
of patients. Grade 5 AEs were not reported, treatment-related grade 1–4 AEs 
can be found in Table 2. 
 
C0002: Are the harms related to dosage or frequency of applying 
obinutuzumab? 
No evidence was found to answer this research question. 
 
C0005: What are the susceptible patient groups that are more likely  
to be harmed through the use of obinutuzumab? 
Obinutuzumab can cause fetal B-cell depletion in pregnant women. Further-
more, it can lead to a Hepatitis B virus (HBV) reactivation that may result in 
fulminant hepatitis, hepatic failure and death. Reactivations have been report-
ed in hepatitis B surface antigen (HBsAg)-positive as well as in hepatitis B 
core antibody (anti-HBc)-positive patients [2].  
  
most common AEs in 
both treatment groups: 
neutropenia, 
thrombocytopenia, 
infusion-related 
reactions 
discontinuation  
due to AEs: 
O-B: 11.3% 
B: 15.7% 
HBV reactivation and 
fetal B-cell depletion  
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Table 2: Most frequent treatment-related adverse events in the whole study population 
Adverse event/Laboratory 
abnormalities (according to CTCAE) 
Obinutuzumab-bendamustine 
(n = 194) 
Bendamustine 
(n = 198) 
Any grade (%) Grades 3–4 (%) All Grades (%) Grades 3–4 (%) 
Adverse reactions reported in ≥ 5% of patients with indolent NHL,  
which are at least 2% greater in the obinutuzumab-bendamustine group 
Infusion-related reactions11 69 11 63 6 
Neutropenia 35 33 28 26 
Constipation 19 0 16 0 
Dyspepsia 5 0 3 0 
Pyrexia 18 1 14 0 
Asthenia  11 1 8 0 
Upper respiratory tract infection 13 2 8 1 
Sinusitis 12 1 5 0 
Urinary tract infection 10 3 6 0 
Nasopharyngitis 9 0 4 0 
Arthralgia 12 0 5 0 
Pain in extremity 9 1 4 0 
Cough 26 0 17 0 
Nasal congestion 7 0 2 0 
Pruritus 9 0 6 0 
Post-baseline laboratory abnormalities in ≥ 5% of patients with indolent NHL,  
which are at least 2% greater in the obinutuzumab-bendamustine group 
Neutropenia  75 52 77 42 
Leukopenia 86 47 88 34 
Lymphopenia 99 93 99 85 
Hypocalcaemia 38 2 26 2 
Hypophosphataemia 41 7 38 7 
ALT/SGPT increased 35 1 31 4 
Elevated creatinine 87 4 92 2 
Creatinine clearance (decreased) 58 6 61 4 
Abbreviations: ALT = alanine aminotransferase, CTCAE = Common Terminology Criteria for Adverse Events,  
SGPT = Serum glutamic pyruvic transaminase 
 
 
 
                                                             
11 Defined as any related adverse reaction that occurred during or within 24 hours  
of infusion 
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7.2 Clinical efficacy and safety  
– further studies 
The GAUGUIN study was an open-label, multicentre, non-randomised, dose-
escalating phase I/II trial assessing the safety and efficacy of two different 
doses of obinutuzumab in relapsed/refractory indolent NHL [25]. 40 patients 
were enrolled, of which 34 patients had FL and 22 were rituximab refractory. 
Patients either received 8 cycles of obinutuzumab as a flat dose of 400 mg on 
days 1 and 8 of cycle 1 and also on day 1 of cycles 2–8 (400/400 mg) or 1,600 mg 
on days 1 and 8 of cycle 1 and 800 mg on day 1 of cycles 2 to 8 (1,600/800 mg). 
The overall response rate (ORR) at the end of treatment was 55% (95% CI 
32%–76%, CR: 9%) in the 1,600/800 mg group compared to 17% (95% CI 
4%–41%, no complete responders) in the 400/400 mg group. The median PFS 
was 6.0 months (range: 1.0–33.9 months) in the 400/400 mg arm and 11.9 
months (range: 1.8–33.9 months) in the 1,600/800 mg arm. Most frequent AEs 
were infusion-related reactions (IRRs), which occurred in 73% of patients, of 
which two patients, both from the 1,600/800 mg arm, had grade 3–4 IRRs. 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of obinutuzumab? 
In Austria, obinutuzumab is available as a 1,000 mg concentrate for solution 
for infusion at € 3,668.20 [26]. 
In patients with relapsed/refractory FL, the recommended and FDA-ap-
proved dose is 1,000 mg administered as an intravenous infusion on days 1, 
8, and 15 of a cycle 1 (28 days). In the following cycles 2–6 1,000 mg are rec-
ommended on each respective day 1. After cycle 6, 1,000 mg should be ad-
ministered every 2 months for 2 years [2]. According to this treatment regi-
men, costs of € 73,364 would incur for 6 cycles and 2 years of obinutuzumab 
monotherapy. 
Additional costs incur due to the combination therapy with bendamustine, 
which is administered at a dose of 90 mg/m² on days 1 and 2 of cycles 1–6 
[2]. Assuming a body surface of 1.70 m², total costs of about € 35,207.58 would 
incur for 6 treatment cycles of combination therapy. 
 
 
 
GAUGIN: 
efficacy of 
obinutuzumab in 
relapsed/refractory 
indolent NHL 
ORR 1,600/800 mg: 55% 
ORR 400/400 mg: 17% 
estimated costs for  
6 treatment cycles and  
2 years of 
obinutuzumab 
monotherapy: € 73,364 
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9 Ongoing research 
In June 2016, a search in databases www.clinicaltirals.gov and 
www.clinicaltrialsregister.eu was conducted. The following ongoing  
phase III trial is investigating obinutuzumab in patients with indolent NHL: 
 NCT01332968: A multicentre, phase III, open-label randomised study 
in previously untreated patients with advanced indolent non-Hodg-
kin’s lymphoma evaluating the benefit of GA101 (RO5072759) + chem-
otherapy compared to rituximab + chemotherapy followed by GA101 
or rituximab maintenance therapy in responders. Estimated study com-
pletion date is March 2017. 
Various phase I and II studies are currently ongoing in different treatment 
lines in patients with indolent NHL, either using obinutuzumab monother-
apy or in combination (e.g. NCT01995669, NCT02393157, NCT01889797 and 
NCT00825149). 
 
 
 
10 Discussion 
In April 2016, the CHMP adopted a positive opinion for the extension of in-
dication of obinutuzumab in combination with bendamustine followed by ob-
inutuzumab maintenance treatment for patients with relapsed/refractory FL. 
Obinutuzumab has been approved in combination with chlorambucil for the 
first-line treatment of CLL since July 2014 [3, 4]. 
In the US, obinutuzumab was approved by the FDA in 2013 as a combina-
tion therapy for the treatment of previously untreated CLL patients. Obinu-
tuzumab in combination with bendamustine, followed by obinutuzumab mo-
notherapy, has been approved for the treatment of patients with relapsed/re-
fractory FL since February 2016 [2].  
The FDA approval was based on the pre-planned interim analysis of the 
GADOLIN trial, which is currently only available in abstract form [5]. This 
open-label, multicentre, randomised phase III study enrolled 392 indolent 
NHL patients (81% with FL), who either received obinutuzumab plus ben-
damustine and subsequent obinutuzumab maintenance treatment or benda-
mustine alone. PFS-IRF and PFS-IA were significantly improved (PFS-IRF: 
p < 0.0001, PFS-IA: p < 0.0001) in the obinutuzumab-bendamustine group 
compared to the bendamustine arm, though PFS-IRF was not reached and cor-
respondent data is not available. The study endpoint, OS, was reached in nei-
ther treatment group. OR rates indicated no difference between the two treat-
ment regimens (obinutuzumab-bendamustine: 78.7%, bendamustine: 74.7%). 
There was no difference in OR and an initial overlap of the Kaplan-Meier 
curves for PFS (FL patients) at around six months. The two curves separated 
approximately after the induction time was finished. Therefore, it would be 
of great interest to determine to which extent PFS improvement was conferred 
to obinutuzumab maintenance treatment in contrast to obinutuzumab-benda-
mustine combination therapy.  
1 phase III study is 
investigating 
obinutuzumab in 
indolent NHL patients 
numerous ongoing 
phase I and phase II trials 
in different  
treatment lines  
positive opinion  
by the CHMP: 
obinutuzumab for 
relapsed/refractory FL 
approved by the  
FDA in 2016 
GADOLIN:  
PFS improvement, no 
difference in OR, and OS 
was not reached 
PFS improvement: 
maintenance vs 
combination treatment 
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In terms of safety outcomes, the most common grade 3–4 AEs in the obinu-
tuzumab-bendamustine as well as in the bendamustine group were neutro-
penia (33% vs 26.3%), thrombocytopenia (10.8% vs 16.2%) and infusion-re-
lated reactions (10.8% vs 5.6%). Pneumonia and neutropenia were the most 
frequent reported serious AEs in both treatment groups. Regarding health-
related quality of life (HRQoL), no notable differences in the average scores 
between the two treatment groups in any of the FACT-Lym5 subscales, either 
over time during the treatment period or during follow-up, could be identi-
fied. 
The trial was discontinued early at the pre-planned interim analysis due to 
significantly improved PFS results, though PFS-IRF was not reached. The 
early termination caused a lack of long-term OS data. Therefore, the current 
OS results are immature and should be reconsidered when long-term data is 
available. Further follow-up will be necessary to exclude any risks of late side 
effects as well as negative effects on QoL. 
As obinutuzumab has been approved for refractory/relapsed FL based on in-
terim analysis only, available solely in abstract form, no detailed information 
exists about the study. Thus, data on subgroup analysis are missing. It is 
therefore impossible to exclude any disadvantages for specific patient groups. 
For instance, since the number of prior therapies was ranging from 1 to 10, it 
would be of interest if patients who were heavily pretreated showed the same 
PFS benefit as patients who received 1–2 lines of prior therapy. In addition, 
the early termination of the trial may negatively influence the probability that 
a nominally statistical finding actually represents a true effect [27]. 
In general, NHL is more frequently diagnosed in people aged 65–74, of which 
the majority of patients are diagnosed at an advanced stage of disease [9, 15]. 
Since patients were on average 63 years old and had an ECOG score between 
0 and 1 in about 95% of cases, the study population did not reflect the affect-
ed FL patients in clinical practice. 
A kinase inhibitor called idelalisib has been approved by the EMA and the 
FDA since 2014. Idelalisib received marketing authorisation for the treatment 
of patients with relapsed FL who received at least two prior systemic therapies 
[28, 29]. It is currently under close monitoring due to severe complications 
that led to death in some cases [22]. Dependent on the safety profile resulting 
from this monitoring process, idelalisib could be used as a future compara-
tor to yield information as to which drug the patients benefit from most. It 
may also be considered to add idelalisib to obinutuzumab to offer an alter-
native treatment option for relapsed/refractory FL.  
Total costs of about € 73,364 would incur for 6 treatment cycles of combina-
tion therapy and 2 years of obinutuzumab monotherapy, not including the 
treatment of side effects. Even though the treatment with obinutuzumab-ben-
damustine is costly, the associated improvement in PFS with this therapy 
should not be neglected. However, the lack of mature OS data, in addition to 
the fact that there was no difference in OR, highlight the need for long-term 
data. Further, a long-term safety profile as well as further QoL data will be 
necessary to exclude any risks of late side effects. In addition, the original arti-
cle presenting the study will be necessary to identify potential advantages and 
disadvantages for specific subgroups. Finally, idelalisib, which is currently 
under close monitoring due to severe AEs, could be used as another compar-
ator or as a combination treatment option with obinutuzumab in the future, 
if it shows manageable AEs. 
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12 Appendix 
Table 3: Characteristics of the GADOLIN trial 
Title: A study to investigate the efficacy and safety of bendamustine compared with bendamustine + obinutuzumab 
(GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma (GADOLIN) [2, 23] 
Study identifier NCT01059630, EudraCT Number 2009-015504-25, GAO4753g, GADOLIN 
Design Open-label, multicentre, randomised phase III study 
Duration Data analysis cut-off: 2014-09-01 
Median follow-up: 21 months; number of patients who 
were still participating in the study at median follow-up: 
obinutuzumab + bendamustine: n = 149 
bendamustine: n = 141 
Funding Roche Registration Ltd 
Hypothesis Superiority 
The study was designed to show a prolonged PFS in patients treated with obinutuzumab plus 
bendamustine compared to those who received bendamustine alone. The primary endpoint (PFS) 
was assessed by an independent radiology facility (IRF), with 80% power to detect 43% 
improvement in median PFS. 
Treatments  
groups 
Intervention Obinutuzumab was administered as follows:  
cycle 1: 1,000 mg on days 1, 8 and 15; cycles 2–6: 1,000 mg 
on day 1; followed by 1,000 mg every 2 months for up to 
2 years) plus bendamustine (cycles 1–6: 90 mg/m2/day on 
days 1 and 2). After CR, PR or SD, patients received 
obinutuzumab maintenance therapy: 1,000 mg every 
two months for two years or until progression. 
Control Bendamustine was administered in cycles 1–6:  
120 mg/m2/day on days 1 and 2. 
Endpoints and 
definitions 
Progression-free survival 
(primary endpoint) 
PFS Defined as the time from randomisation to first 
occurrence of progression or relapse, or death 
Overall survival OS Defined as the time from randomisation to death 
Best overall response OR Best response of CR/PR within 12 months of study start 
Results and analysis  
Analysis  
description 
Primary analysis 
No information is available on the included patient population regarding efficacy and safety. 
Patient-reported HRQoL analyses included all randomised patients in the intent-to-treat 
population who had a non-missing baseline and at least one post-baseline patient-reported 
outcome assessment (PRO). Descriptive statistics for recorded values at each visit and changes 
from baseline were presented with the use of the PRO analysis set, for each PRO endpoint. 
PFS was analysed by a stratified log-rank test. 
Analysis  
population  
Inclusion  Age ≥ 18 years  
 History of histologically documented CD20+, indolent NHL 
 Refractory to any previous regimen containing rituximab 
 Previously treated with a maximum of four unique chemotherapy-
containing treatment regimens 
 All patients must have at least one bi-dimensionally measurable lesion 
(> 1.5 cm in its largest dimension by CT scan) 
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Analysis  
population  
(continuation) 
Exclusion  Prior use of any monoclonal antibody (other than anti-CD20)  
within 3 months 
 Chemotherapy or other investigational therapy within 28 days 
 Prior treatment with bendamustine (within 2 years of the start  
of study treatment) 
 Prior allogeneic stem cell transplant 
 History of severe allergic or anaphylactic reactions to monoclonal 
antibody therapies  
 History of sensitivity to mannitol 
 Central nervous system lymphoma or histological evidence of 
transformation to high-grade or diffuse large B-cell lymphoma 
 History of other malignancy that could affect compliance with the 
protocol or interpretation of results 
 Evidence of significant, uncontrolled concomitant diseases that could 
affect compliance with the protocol or interpretation of results 
 Known active bacterial, viral, fungal, mycobacterial, parasitic or other 
infection (excluding fungal infections of nail beds) or any major episode 
of infection requiring treatment with intravenous antibiotics or 
hospitalisation within 4 weeks 
 Vaccination with a live vaccine a minimum of 28 days prior  
to randomisation 
 Recent major surgery (within 4 weeks), other than for diagnosis 
 Presence of positive test results for hepatitis B or hepatitis C 
 Known history of HIV seropositive status 
 Positive test results for human T-lymphotropic virus type I (HTLV 1) 
virus in endemic countries 
 Women who are pregnant or lactating 
 Agreement to use an effective form of contraception for the duration 
of the study 
 Ongoing corticosteroid use > 30 mg/day prednisone or equivalent 
Characteristics12  Obinutuzumab-
bendamustine 
Bendamustine 
Median age, years (range) 63 (34–87) 
Gender:% 
♂: 56.7 
♀: 43.4 
♂: 58.4 
♀: 41.6 
Number of prior treatments, 
median (range) 
2 (1–10) 
Median time since initial diagnosis, 
years 
3 
ECOG 0–1 95.4 95.5 
Ann Arbor stage IV disease 60.3 52.7 
Prior rituximab + chemotherapy 
treatment,% 
80.4 77.7 
Prior treatment with rituximab 
monotherapy,% 
19.6 22.3 
Follicular lymphoma,% 79.9 82.2 
Marginal zone lymphoma,% 13.9 9.4 
Small lymphocytic lymphoma,% 6.2 7.9 
Abbreviations: CR = complete response, CT = Computer tomography, ECOG = Eastern Cooperative Oncology Group, 
HRQoL = health-related quality of life, PR = partial response 
                                                             
12 Data based on the whole study population (indolent NHL patients) of the GADOLIN study  
